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Based on mouse model for sickle cell
anaemia, skin fibroblasts were first
reprogrammed into iPSC. These iPSC were
applied targeted genetic therapy, in order to
repair the mutation responsible for the
disease. Lastly, repaired iPSC were induced
to differentiate into blood cell precursors
and were subsequently transplanted into the
bone marrow in the same anaemic mice. As
a result, they were able to produce normal
red blood cells, recovered from the anaemia.
Medical applications of iPSC
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Gene repair coupled with cell-
replacement therapy
This involves genetically manipulation of iPSC
to make them either:
a) Produce a protein
b) Silence the expression of a protein
c) It is possible even to correct specific
mutations by means of homologous
recombination in iPSC
Establishing a pool of cells
In order to let iPSC proliferate and form a
pool that will serve as a source of cells for
differentiating and transplanting into patient's
cells-lacking tissues. This pool may serve to
renew a cell population that has been or is
being destroyed by a pathology.
 iPSC represent a new tool for modeling particular diseases in culture, i.e. in vitro. This enables the study of particular human diseases’
pathogenesis, identification of new diagnosis markers or new therapeutic agents, as well as serving as a basis for other iPSC applications.
The generation of disease models based on iPSCS is possible either since these cells retain the same disease genotype as that of the patient from whom they were derived
(interesting for genetic diseases modeling); or otherwise, thanks to the possibility of modifying iPSC in order to make them acquire the phenotype of interest, by means of
genetic manipulation or not.
 Studying pathogenesis: studying the molecular basis of a disease is an essential to the identification of new diagnosis markers and new therapeutic agents. These
models also offer access for determining several aspects of the affected cells in the disease: such as metabolic abilities, drug susceptibilities, resistance or
susceptibility to suffer the disease, etc.
 Disease treatment: disease models in a dish allow for testing different drugs on the affected cells, which may be patient-specific or not. This represents a very
effective way for determining the most effective therapeutic agent.
Since 2008, when first disease model was defined – it showed the phenotype for spinal muscular atrophy (SMA), many iPSC lines have been established, including models
for both hereditary and sporadic diseases. However many requirements are needed in order to accept an iPSC line as a disease model, and they are not fulfilled yet. Few
from all the large list
of already modeled diseases are:
• SMA
• Parkinson’s Disease
• Alzheimer’s Disease
• Type 1 Diabetes mellitus
• Fanconi’s anaemia
• Sickle-cell anaemia iPSC colonies derived from fibroblasts iPSC differentiation
of a PD patient with SNCA triplication into dopaminergic neurons
Central image: Procedure for generating a disease model would be as depicted in the scheme - iPSC can be achieved from differentiated somatic cells belonging to a
patient with the disease of interest (skin biopsy) and subsequent culture and differentiation will provide the in vitro model for the disease.
 Drug studies or testing on iPSC lines include activities which range from evaluating
the effect of a drug on a particular or many cell types, either healthy or affected by a
disease, to analyzing the response of one patient's cells to one or various drugs.
Many combinations are possible: testing may be carried out either on healthy or affected iPSC-
derived cell types, which in turn may be patient-specific or not. Simultaneously, pharmacological
actions may be evaluated at a disease level or at a personalized level. The variety of possible trials
that may be performed include:
 Studying cellular response to a drug, either on healthy or affected cells.
 Studying the properties of a particular drug, such as toxicity, on different cell lines that show the
same pathological condition.
 Comparing the effect of different drugs either in one or various disease models, for instance in
the event they represent different diseases which affect the same cell type.
 Personalized therapies by testing drugs on patient-specific iPSC-derived cultures: firstly
choosing the best drug for the treatment of the obtained cells from a patient's iPSC, and
secondly, subsequent analysis of the appropriate levels, dosages, toxicity, adverse effects
iPSC would simplify pharmaceutical procedures because drugs could be tested in high quantities of
specialized cells, thus avoiding the use of animals, or at least, reducing their number. Through the
development of iPSC lines, metabolic in vitro studies could be improved, as could toxicological trials.
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 Basic research is the study -discovery and understanding- of fundamentals, in this case, related to
biology fields. iPSC offer here several possibilities:
 Studying iPSC themselves: iPSC still account with limiting features when trying to use them in clinics, so further
research is needed to solve them. Furthermore, reprogramming methods must be improved and cheapened; in vitro
iPSC differentiation programs must be standardized; and importantly, both similarities and differences in comparison
with ESC have yet to be unraveled.
 Studying cell biology: iPSC prevent the need for living tissues since they can give rise to any tissue’s cells.
 Studying early embryonic development: iPSC cultures may allow researchers to follow cellular differentiation during
initial stages of development, and even to find out how to orchestrate it in vitro.
 Studying replication and differentiation-associated pathology: it is not know yet what precise mechanisms underlie
some illnesses which develop due to replication or differentiation defects, such as tumor formation. In this sense,
these mechanisms could be extrapolated from those studied in iPSC. A better knowledge would help us to develop
new therapeutic tools.
Within the broad field of regenerative medicine, iPSC are just one more tool for performing stem cell-based therapies,
therefore called iPSC-based therapies.
This kind of treatment consists of iPSC acquisition from a patient's somatic cells by means of reprogramming. iPSC achievement, combined with
their main properties i.e. unlimited proliferation, pluripotency, and in vitro state, is the basis for patient-specific treatment as far as iPSC-
derived cells may be transplanted back into the patient in an autologous-manner. This application may involve two strategies, both of which
harness the possibilities offered by the successful prevention of immune rejection: the first is that iPSC may serve as a stem-cell pool, and the
second is that iPSC can provide a means for targeted gene-repair.
Scheme for in vitro reprogramming. From [3]
